Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald Richards

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
JACC. Case Reports|October 10, 2025
Coronary Microvascular Dysfunction Related to Hydroxychloroquine-Induced CardiomyopathyDonald Richards, Deeksha Acharya, Serguei Bannykh, et al.
American Journal of Clinical Oncology|February 3, 2005
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trialNeil Senzer, James Arsenau, Donald Richards, et al.
Cancer Chemotherapy and Pharmacology|March 15, 2017
Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patientsD Mahadevan, Monica Mita, Donald Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2017
Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I TrialVincent Chung, Aaron S Mansfield, Fadi Braiteh, et al.
Journal of Cachexia, Sarcopenia and Muscle|July 28, 2018
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trialTalia Golan, Ravit Geva, Donald Richards, et al.
Cancer Investigation|September 20, 2006
Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancyJohn Nemunaitis, Svetislava J Vukelja, Donald Richards, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2013
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 studyDonald Richards, Darren M Kocs, Alexander I Spira, et al.
Leukemia & Lymphoma|January 15, 2021
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximabRoger M Lyons, Mikhail Shtivelband, Edwin Kingsley, et al.
Journal of Cardiac Failure|November 30, 2024
Utility of Mechanistic Target of Rapamycin Inhibitors in Cardiac SarcoidosisDonald Richards, Hidesato Fujito, Aakash Shanbhag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C StudyCharles S Fuchs, John Marshall, Edith Mitchell, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
JACC. Case Reports|October 10, 2025
Coronary Microvascular Dysfunction Related to Hydroxychloroquine-Induced CardiomyopathyDonald Richards, Deeksha Acharya, Serguei Bannykh, et al.
American Journal of Clinical Oncology|February 3, 2005
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trialNeil Senzer, James Arsenau, Donald Richards, et al.
Cancer Chemotherapy and Pharmacology|March 15, 2017
Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patientsD Mahadevan, Monica Mita, Donald Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2017
Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I TrialVincent Chung, Aaron S Mansfield, Fadi Braiteh, et al.
Journal of Cachexia, Sarcopenia and Muscle|July 28, 2018
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trialTalia Golan, Ravit Geva, Donald Richards, et al.
Cancer Investigation|September 20, 2006
Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancyJohn Nemunaitis, Svetislava J Vukelja, Donald Richards, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2013
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 studyDonald Richards, Darren M Kocs, Alexander I Spira, et al.
Leukemia & Lymphoma|January 15, 2021
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximabRoger M Lyons, Mikhail Shtivelband, Edwin Kingsley, et al.
Journal of Cardiac Failure|November 30, 2024
Utility of Mechanistic Target of Rapamycin Inhibitors in Cardiac SarcoidosisDonald Richards, Hidesato Fujito, Aakash Shanbhag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C StudyCharles S Fuchs, John Marshall, Edith Mitchell, et al.
Pageof 4